The latest approach to rheumatoid arthritis (RA) treatment hasn’t been revolutionized by a single new drug. Instead, it’s been reshaped by updated treatment guidelines, broader use of targeted biologics, a growing wave of more affordable biosimilars, and experimental therapies like vagus nerve stimulation entering clinical trials. Under modern tight-control strategies, about 68% of RA patients now achieve clinical remission within 10 years, a figure that would have been unthinkable two decades ago.
The Current Treatment Sequence
The European Alliance of Associations for Rheumatology (EULAR) released updated RA management recommendations in 2025, and the core strategy follows a step-up approach. Methotrexate remains the recommended first-line drug, ideally combined with a short course of low-dose steroids to control inflammation while the methotrexate takes effect. This hasn’t changed, and for good reason: methotrexate still works well for a large portion of patients and costs a fraction of newer therapies.
What happens next is where treatment has evolved. If methotrexate doesn’t produce an adequate response within three to six months, the current recommendation is to add a biologic. These are lab-engineered proteins that block specific parts of the immune system driving joint inflammation. The most commonly used biologics target a protein called TNF, and they’ve been the backbone of RA treatment for over 20 years. Other biologics block different immune signals, including one called IL-6 or a type of immune cell activation. In a real-world study of 204 patients tracked over 10 years, TNF-blocking biologics were used in about 55% of patients, IL-6 blockers in 34%, and a third class that dampens T-cell activation in about 17%.
A newer class of oral medications called JAK inhibitors can also be added at this stage, but the 2025 guidelines specifically note they should be considered only after careful evaluation of individual risk factors. If the first biologic or JAK inhibitor fails, switching to a different biologic (even one in the same class) or a different JAK inhibitor is the next step. When sustained remission is achieved, medications can be gradually reduced, though stopping entirely often triggers a flare.
JAK Inhibitors and Their Safety Tradeoffs
JAK inhibitors are pills rather than injections, which makes them appealing. Three are approved for RA in the U.S.: tofacitinib, baricitinib, and upadacitinib. They work by blocking enzymes inside immune cells that relay inflammatory signals, and they can be effective when biologics haven’t worked.
However, the FDA requires their strongest safety warning, a boxed warning, on all three. This stems largely from a large randomized trial of tofacitinib that found increased risks of serious heart-related events (heart attack and stroke), certain cancers (particularly lymphoma and lung cancer), blood clots, and death compared to TNF-blocking biologics. Baricitinib and upadacitinib haven’t been studied in an equivalent head-to-head safety trial, but because they work through the same mechanism, the FDA considers them potentially subject to the same risks.
In practice, this means JAK inhibitors are typically reserved for patients who haven’t responded to at least one biologic, or for those whose specific risk profile makes them reasonable candidates. Your rheumatologist will weigh your age, cardiovascular history, cancer history, and smoking status before recommending one.
Biosimilars Are Expanding Access
One of the most practical developments in RA treatment is the growing availability of biosimilars. These are near-identical copies of biologic drugs that cost significantly less than the originals. Six interchangeable biosimilars of adalimumab (the reference product is Humira) are now approved in the U.S. The “interchangeable” designation matters because it means your pharmacist can substitute the biosimilar for the brand-name drug without needing separate approval from your prescriber, just like switching between generic and brand-name pills.
For patients, this translates to lower out-of-pocket costs and fewer insurance battles. The clinical performance of interchangeable biosimilars is required to be indistinguishable from the original, so switching should not affect how well your treatment works.
Precision Medicine Is Getting Closer
One of the biggest frustrations in RA treatment is the trial-and-error process of finding the right drug. Researchers are making progress on blood-based biomarkers that could predict which medication will work for a given patient before they spend months waiting to find out.
For methotrexate, the level of certain immune cells in your blood (specifically a type of regulatory T cell marked by a protein called CD39) can predict whether you’ll respond to the drug with greater than 99% confidence when levels are low, signaling likely non-response. Several genetic variations in genes involved in how the body processes methotrexate have also been linked to treatment success or failure. For TNF-blocking biologics, researchers have identified genetic markers and even patterns of DNA modification in blood cells that distinguish good responders from poor ones. One study found that a specific gene variant in the immune cell protein CD84 predicts responsiveness to etanercept in European patients.
These biomarkers aren’t yet part of routine clinical practice, but they represent a shift toward matching patients with the right drug from the start rather than cycling through options.
Vagus Nerve Stimulation
Perhaps the most unconventional treatment in development is bioelectronic medicine. A miniaturized device implanted near the vagus nerve, which runs from the brain to the gut and helps regulate inflammation, sends small electrical pulses that appear to calm the overactive immune response driving RA.
In a first-in-human randomized trial, 5 out of 9 patients receiving active vagus nerve stimulation met clinical response criteria after 24 weeks. The treatment reduced blood levels of several inflammatory markers, including IL-6, and stabilized or reduced bone erosion on MRI in all but one stimulated patient. These are small numbers from an early trial, and the therapy is not yet approved, but the concept of treating an autoimmune disease with electrical signals rather than drugs is a genuinely different direction. The patients in this trial had multidrug-refractory RA, meaning they had already failed multiple conventional treatments.
What Modern Remission Looks Like
The goal of RA treatment today is remission, not just symptom management. In a real-world cohort study tracking patients over 10 years under a tight-control strategy (where treatment is adjusted every few months based on measured disease activity), 68% achieved clinical remission. About three-quarters of those patients required at least one biologic or targeted therapy beyond methotrexate to get there. This underscores that while methotrexate alone works for some, most patients with moderate to severe RA will eventually need a biologic or JAK inhibitor added to their regimen.
Tight control means regular monitoring, usually every one to three months, with standardized scoring of joint tenderness, swelling, and inflammation markers. If your scores aren’t improving, your treatment gets escalated. This proactive approach, rather than any single drug, is what has driven remission rates to levels that weren’t achievable when treatment adjustments happened less frequently or were based on less structured assessments.